Abstracts Archive - Page 2182 of 2425 - ACR Meeting Abstracts

Abstract Number: 1016 • 2013 ACR/ARHP Annual Meeting
Presenteeism Predicts Sick Leave Better Than Basdai and/Or BASFI In A Longitudinal Cohort Of Patients With Ankylosing Spondylitis (EASIC)
Thien Thi Vinh Nguyen¹, An Tran-Duy², Frank Heldmann³, Jürgen Braun³, Herbert Thijs¹ and Annelies Boonen⁴, ¹Center for Statistics, Hasselt University, Hasselt, Belgium, ²Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Sick leave (SL) is a critical socioeconomic consequence of ankylosing spondylitis (AS). This study aimed at exploring the role of presenteeism relative to BASDAI…
Abstract Number: 1019 • 2013 ACR/ARHP Annual Meeting
Comparison Of Comorbidity Indexes In a Clinical and Administrative Rheumatoid Arthritis Cohort: A Case For The Rheumatic Diseases Comorbidity Index
Bryant R. England¹, Harlan Sayles², Ted R. Mikuls², Dannette S. Johnson³ and Kaleb Michaud⁴, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, Jackson VA and University of Mississippi Medical Center, Jackson, MS, ⁴Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Quantifying comorbidities contribution to disability and mortality is important for assessing prognosis and standardizing cohorts in rheumatic disease research. A comorbidity index has been…
Abstract Number: 1020 • 2013 ACR/ARHP Annual Meeting
The Impact Of Diagnostic Decision Rules Used In Administrative Healthcare Databases On The Frequency Of Rheumatoid Arthritis and Systemic Lupus Erythematosus
John G. Hanly¹, Kara Thompson² and Chris Skedgel¹, ¹Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ²Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: To compare the incidence and prevalence of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) in administrative databases using different diagnostic decision rules. Methods:…
Abstract Number: 1021 • 2013 ACR/ARHP Annual Meeting
Application Of a Novel Measure Of Socioeconomic Status Using Individual Housing Data In Rheumatology Research
Young Juhn¹, Sherine E. Gabriel², Cynthia S. Crowson³, Jennifer Rand-Weaver¹ and Elizabeth Krusemark¹, ¹Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: We recently developed and validated an index of socioeconomic status (SES) termed HOUSES (HOUsing-based index of SocioEconomic Status) to address unavailability of SES measures…
Abstract Number: 1022 • 2013 ACR/ARHP Annual Meeting
Initiation Of Biologic Therapy: The Patient Perspective
Amir Goren¹, Susan C. Bolge², Duncan Brown³, Roxanne Meyer⁴ and Seth Ginsberg⁵, ¹Kantar Health, New York, NY, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Kantar Health, New york, NY, ⁴Janssen Scientific Affairs, LLC, Horsham, NY, ⁵Creaky Joints, New York, NY
Background/Purpose: Current guidelines for the treatment of rheumatoid arthritis (RA) recommend that patients who are not adequately responding to treatment with disease modifying anti-rheumatic drugs…
Abstract Number: 1023 • 2013 ACR/ARHP Annual Meeting
Openness To and Preference For Biologic Therapy Among Patients With Rheumatoid Arthritis Prior To Biologic Initiation: Patient and Prescriber Perspectives
Susan C. Bolge¹, Duncan Brown², Amir Goren³, Roxanne Meyer⁴ and Seth Ginsberg⁵, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Kantar Health, New york, NY, ³Kantar Health, New York, NY, ⁴Janssen Scientific Affairs, LLC, Horsham, NY, ⁵Creaky Joints, New York, NY
Background/Purpose: Currently two modes of administration are available for biologic therapies used to treat rheumatoid arthritis (RA): subcutaneous injection (SQ) and intravenous infusion (IV). Patient…
Abstract Number: 1024 • 2013 ACR/ARHP Annual Meeting
Modeling The Benefit Risk Profiles Of a New Janus Kinase Inhibitor Tofacitinib Compared Tottumour Necrosis Factor Inhibitor Biologic Treatments Incorporating Conjoint Derived Patient Preference Weights
Michael P. Ingham¹, Shannon Cartier², Raphael J. DeHoratius³, Jack McGowan⁴ and Eric Sabot², ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Optum, Eden Prairie, MN, ³Medical Affairs, Janssen Services, LLC, Horsham, PA, ⁴Janssen Services, LLC, Horsham, PA
Background/Purpose: Tofacitinib (Tofa) was recently approved in the U.S. There are no data comparing the benefit risk profile of Tofa to tumor necrosis factor inhibitors…
Abstract Number: 1025 • 2013 ACR/ARHP Annual Meeting
Mapping The Health Assessment Questionnaire On a Preference Based Utility Measure In a Large Canadian Rheumatoid Arthritis Cohort: Results From The Ontario Best Practices Research Initiative
Mark Tatangelo¹, George A. Tomlinson² and Claire Bombardier³, ¹Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: mANMClinical trials are limited in demonstrating the cost effectiveness of biologic therapies, as these studies often do not collect measures required for economic analysis. …
Abstract Number: 1026 • 2013 ACR/ARHP Annual Meeting
Impact Of Basing Rheumatoid Arthritis Disease Activity Measurement and Treatment Recommendations On Patient Instead Of Physician Joint Assessments
Yomei Shaw¹, Daisy Bang², Heather Eng³, Stephen R. Wisniewski⁴, Mark S. Roberts¹ and Marc C. Levesque⁵, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Current guidelines recommend treatment for rheumatoid arthritis (RA) be informed by a measure of disease activity such as the Disease Activity Score-28 (DAS28-CRP), which…
Abstract Number: 1027 • 2013 ACR/ARHP Annual Meeting
Factors Associated With Decisions To Adjust Therapy For Rheumatoid Arthritis Patients In Moderate To High Disease Activity
Yomei Shaw¹, Chung-Chou H. Chang^2,3, Heather Eng⁴, Ilinca D. Metes⁵, Stephen R. Wisniewski⁶, Mark S. Roberts¹ and Marc C. Levesque⁷, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁵Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The American College of Rheumatology (ACR) recommends treating rheumatoid arthritis (RA) to the target of low disease activity or remission with traditional and biologic…
Abstract Number: 1028 • 2013 ACR/ARHP Annual Meeting
Development Of Patient-Reported Outcomes Measurement Information System (PROMIS®) Gastrointestinal (GI) Symptoms Item Bank
Dinesh Khanna¹, Lin Chang², Gil Y. Melmed³, Roger Bolus⁴, Puja Khanna¹, Ron Hays⁵ and Brennan Spiegel^6,7, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Medicine, Division of Digestive Diseases, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, ³Inflammatory Bowel Disease Center, Cedar-Sinai Medical Center, Los Angeles, CA, ⁴Research Solutions Group, Encinitas, CA, ⁵Medicine, University of California, Los Angeles, Los Angeles, CA, ⁶Gastroenterology; Health Policy and Management, Cedars-Sinai Health System and UCLA School of Medicine and Public Health, Los Angeles, CA, ⁷VA Greater Los Angeles Healthcare System, Los Angeles, CA
Background/Purpose: The National Institutes of Health PROMIS® roadmap initiative is a cooperative research program designed to develop, evaluate, and standardize item banks to measure patient-reported…
Abstract Number: 1029 • 2013 ACR/ARHP Annual Meeting
Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea
Yoon-Kyoung Sung^1,2, Kazuki Yoshida^2,3, Femke H.M. Prince^2,4, Michelle A. Frits², Jung-Yoon Choe⁵, Won Tae Chung⁶, Jisoo Lee⁷, Eun-Mi Koh⁸, Dae-Hyun Yoo⁹, Simon M. Helfgott², Nancy A. Shadick¹⁰, Michael E. Weinblatt¹¹, Sang-Cheol Bae¹ and Daniel H. Solomon², ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ⁴Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁵Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ⁷Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ⁸Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ¹¹Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Quality of life (QOL) is a well-established outcome for rheumatoid arthritis (RA) trials. To perform trials with QOL as an outcome involving many countries,…
Abstract Number: 1030 • 2013 ACR/ARHP Annual Meeting
Readability of Participant Information and Consent Forms for Rheumatology Clinical Trial Participants
Stephen Hall¹, Gail Grant² and Christina Meyer², ¹Melbourne Rheumatology, Melbourne, Australia, ²emeritus research, melbourne, Australia
Background/Purpose: To determine the readability of written information (Participant Information and Consent Forms [PICS]) provided to clinical trial participants prior to enrolment into a clinical…
Abstract Number: 1031 • 2013 ACR/ARHP Annual Meeting
Health Literacy Predicts Discrepancies Between Traditional Written Rheumatoid Arthritis Patient Assessments and Verbally-Administered Assessments
Joel M. Hirsh¹, Lisa A. Davis^2,3,4, Itziar Quinzanos^5,6,7, Angela Keniston⁸ and Liron Caplan^6,9, ¹Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ²Division of Rheumatology, Univ. of Colorado Sch. of Medicine, Aurora, CO, ³Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁴Denver Veterans Affairs Medical Center, Denver, CO, ⁵Department of Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁶Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, ⁷Department of Medicine, Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁸Department of Medicine, Denver Health and Hospital Authority, Denver, CO, ⁹Department of Medicine, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Patient assessments of disease activity (PtGA) and general health (GH) measured by visual analog scale (VAS) are widely used in rheumatoid arthritis (RA) clinical…
Abstract Number: 990 • 2013 ACR/ARHP Annual Meeting
Utilizing Facebook Chats To Convey Health Information To Lupus Patients At The Systemic Lupus Erythematosus – Antiphospholipid Syndrome Center Of Excellence At Hospital For Special Surgery
Nadine H. Spring¹, Elyse Bernstein², Su Jin Kim³, Monica C. Richey¹, Jessica Rowshandel⁴ and Jane E. Salmon¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Public Relations, Hospital for Special Surgery, New York, NY, ³Department of Social Work Programs, Hospital for Special Surgery, New York, NY, ⁴S.L.E. Lupus Foundation, New York, NY
Background/Purpose: The SLE-APS Center of Excellence at Hospital for Special Surgery (HSS) uses Facebook chats as a means to increase awareness, reach a wider audience,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].